Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs)’ (LBA-4) was presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
Questions
- What are the limitations of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia? (0:17)
- Could you tell us a little about asciminib and its mechanism of action? (2:45)
- What were the aims and design of the ASCEMBL study? (5:37)
- What were the efficacy and safety findings of the ASCEMBL study? (7:15)
- What will be the next steps in the clinical development of asciminib? (8:52)
Speaker Disclosures: Prof. Andreas Hochhaus has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
